- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
Bill Riesner serves as Vice President, Market Access at Viking Therapeutics. He brings more than 20 years of biopharmaceutical experience in pricing, payer strategy, evidence and launch execution across endocrine and metabolic therapies. Before joining Viking, Bill held senior market access roles at Amgen and Eli Lilly, including leading U.S. access for the tirzepatide launch. […] The post Bill Riesner, J.D., M.B.A. appeared first on Viking Therapeutics.
The post Treatment with Oral VK2735 Results in Significant Weight Loss: The Randomized, Placebo-Controlled, Dose-Finding, VENTURE-Oral Study appeared first on Viking Therapeutics.